Attached files
| file | filename |
|---|---|
| EX-32.1 - EXHIBIT 32.1 - CALMARE THERAPEUTICS Inc | s103020_32-1.htm |
| EX-31.1 - EXHIBIT 31.1 - CALMARE THERAPEUTICS Inc | s103020_31-1.htm |
| EX-31.2 - EXHIBIT 31.2 - CALMARE THERAPEUTICS Inc | s103020_31-2.htm |
| EX-10.44 - EXHIBIT 10-44 - CALMARE THERAPEUTICS Inc | s103020_ex10-44.htm |
| EX-10.45 - EXHIBIT 10-45 - CALMARE THERAPEUTICS Inc | s103020_ex10-45.htm |
| 10-K - FORM 10-K - CALMARE THERAPEUTICS Inc | s103020_10k.htm |
Exhibit 32.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT of 2002
In connection with the Quarterly Report of Calmare Therapeutics Incorporated (the “Company”) on Form 10-K for the period ended December 31, 2015 as filed with the Securities and Exchange Commission on the date hereof (the “Quarterly Report”), Thomas P. Richtarich, Chief Financial Officer of the Company, certifies, pursuant to 18 U.S.C. section 1350 of the Sarbanes-Oxley Act of 2002, that:
| 1. | The Quarterly Report, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| 2. | The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
| By: | /s/ Thomas P. Richtarich | ||
| Thomas P. Richtarich | |||
Principal Financial Officer
|
|||
Dated: April 14, 2016